



DRUG PRIOR AUTHORIZATION COMMITTEE AGENDA

Date: September 16, 2021

Time: 10:00am – 3:00pm (CST)

Location: Webex

[Join Webex Meeting](#)

Meeting number (access code): 17771 91 0976

Meeting password: f2Xin7W7uaX

Join from a Video System/Application

Dial [1771910976](tel:1771910976) @stateofmo.webex.com

Or dial 173.243.2.68 and enter the meeting number

Join from a Mobile Device (attendees only)

[1-650-479-3207](tel:16504793207) Call-in toll number (US/Canada)

[* Click HERE for Meeting Documents *](#)

Opening Statements/Updates

10:00 – 10:05	Welcome, Announcements and Introductions	Chairperson
10:05 – 10:15	Minutes Review	Discussion/Approval
10:15 – 10:25	Pharmacy Program/Budget Update	Elizabeth Short
10:25 – 10:35	Review of Prior Authorization Meeting and Public Hearing	Josh Moore

Old Business

10:35 – 10:45	Implementation Schedule – Criteria for Previously Approved Clinical Edits, Step Therapies and PA's	Josh Moore
---------------	--	------------

New Business

10:45 – 11:00	Proposed Actions - New Drug/Product Review (See Website and Attached Summary) <ul style="list-style-type: none">i. Open Accessii. Clinical Edit/Step Therapyiii. PDL Agentsiv. Prior Authorization	Josh Moore
---------------	--	------------

Clinical and Fiscal Edit Review

11:00 – 11:45	<u>Existing Criteria</u> <ul style="list-style-type: none">i. Emsamii. Immunoglobuliniii. Lambert-Eaton Myasthenic Syndrome (LEMS)iv. Neuromyelitis Optica Spectrum Disorder (NMOSD)v. Nuedextavi. Oxandrinvii. Palforziaviii. Ranexaix. Transthyretin-Mediated Amyloidosis (ATTR)x. Xcopri <u>New Criteria or Revision of Existing Criteria</u> <ul style="list-style-type: none">xi. Aduhelmxii. Botulinum Toxinxiii. Equetro	Josh Moore
---------------	---	------------

- xiv. Narcolepsy Inhibitors
- xv. Psychotropic Medications Polypharmacy
- xvi. Selective Serotonin Reuptake Inhibitor (SSRI)
- xvii. Serotonin and Norepinephrine Reuptake Inhibitors (SNRI)

Preferred Drug List Edit Review

11:45 – 1:00 Existing Criteria Josh Moore

- i. ARBs and ARBs/Diuretic Combinations
- ii. ARBs/CCB Combinations
- iii. Beta Blockers and Beta Blockers/Diuretic Combinations
- iv. Calcium Channel Blockers, Dihydropyridine
- v. Calcium Channel Blockers, Non-Dihydropyridine
- vi. Direct Renin Inhibitors and Combinations
- vii. Dry Eye Disease Agents
- viii. Niacin Derivatives
- ix. PAH, ETRAs
- x. PAH, Prostacyclins Inhaled
- xi. PAH, Prostacyclins Oral
- xii. Sympatholytics

New Criteria or Revision of Existing Criteria

- i. ACE Inhibitors and ACE Inhibitors/Diuretic Combinations
- ii. ACE Inhibitors/Calcium Channel Blocker Combinations
- iii. ADHD, Amphetamines Long Acting
- iv. ADHD, Amphetamines, Short Acting
- v. ADHD, Methylphenidate Long Acting
- vi. ADHD, Methylphenidate, Short Acting
- vii. ADHD, Non-Stimulants
- viii. Anticoagulants
- ix. Anticonvulsants, Rescue Agents
- x. Antiplatelets
- xi. Homozygous Familial Hypercholesterolemia (HoFH) Agents
- xii. PAH, PDE5/SGC Stimulators
- xiii. PAH, Prostacyclins Injectable
- xiv. PCSK9 Inhibitors
- xv. Proton Pump Inhibitors
- xvi. Statins (HMG-CoA Reductase Inhibitors) and Combinations
- xvii. Triglyceride Lowering Agents

Break

1:00 – 1:15 Lunch

Program Utilization Information – Conduent Update

1:15 – 1:30 Reports Jennifer Colozza

- i. Call Center Statistics
- ii. New Drug Statistics
- iii. “Top 25” Drugs by Cost/Claims

Other Business/Closing Comments

1:30 – 1:50 Other Business

*Informal comments will be accepted from members of the audience at various points in the agenda.
Times noted are approximate, agenda may move more quickly.*

NEXT MEETING: December 16, 2021

***Subject to change: Beginning October 2021, the Drug Prior Authorization Committee (DPAC) and Drug Utilization Review (DUR) meetings will allow in-person attendance for board members and associated MO HealthNet staff only. Webex will remain available for all other attendees.**

<p><i>Motion to Close:</i> <i>I move that this meeting be closed, and that all records and votes pertaining to and/or resulting from this closed meeting be closed, under Section 610.021 Subsection (14),(5) RSMo for proceedings required pursuant to a disciplinary order <u>concerning medical, psychiatric, psychological, or alcoholism or drug dependency diagnosis or treatment of specific licensees.</u></i></p>
